Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
5-Year IF – 2.0, IF – 1.9, JCI (2024) – 0.43
Scopus CiteScore – 4.3
Q1 in SJR 2024, SJR score – 0.598, H-index: 49 (SJR)
ICV – 161.00; MNiSW – 70 pts
Initial editorial assessment and first decision within 24 h

ISSN 1899–5276 (print), ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2017, vol. 26, nr 9, December, p. 1351–1358

doi: 10.17219/acem/64940

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Oral mucositis and saliva IgA, IgG and IgM concentration during anti-tumor treatment in children suffering from acute lymphoblastic leukemia

Elżbieta J. Pels1,A,B,C,D,E,F

1 Department of Paedodontics, Medical University of Lublin, Poland

Abstract

Background. Oral mucositis is a problem occurring within the oral cavity, which is the most difficult to deal with during anti-tumor treatment. The first symptom reported by the patient is discomfort. Salivary immunoglobulins play an important role in pathological processes occurring in the oral cavity.
Objectives. The study objective was to assess the occurrence of oral mucositis and to assess changes in the saliva IgA, IgG, and IgM concentration in children with acute lymphoblastic leukemia during antitumor treatment.
Material and Methods. The study included 78 children with acute lymphoblastic leukemia (ALL) and a control group of healthy children. All the participants underwent 3 examinations.
Results. Mucosal opacity followed by redness usually occurred within 2–4 days after the methotrexate infusion. The most severe lesions of the oral mucosa were observed after the 1st month of chemotherapy. Correlations were found between hard-to-heal wounds and ulcers and blood morphology parameters. The mean saliva IgA concentration in children with ALL during chemotherapy was significantly lower than in children in the control group. A comparison of the mean saliva IgG in a given patient in subsequent examinations revealed a significant saliva IgG decrease occurring between the 1st and 3rd examinations.
Conclusion. Wounds and ulcers that were difficult to heal were related to blood morphology parameters. A low salivary IgA concentration in children with ALL may result in the development and potentiation of oral lesions typical of mucositis during anti-tumor treatment. A significant decrease in salivary IgG and IgM concentrations in children with ALL during chemotherapy may cause potentiation of pathological lesions in the oral mucosa.

Key words

children with oncological diseases, oral mucositis, saliva immunoglobulins, acute lymphoblastic leukemia

References (40)

  1. Tolentino Ede S, Centurion BS, Ferreira LH, Souza AP, Damante JH, Rubira-Bullen IR. Oral adverse effects of head and neck radiotherapy: Literature review and suggestion of a clinical oral care guideline for irradiated patients. J Appl Oral Sci. 2011;19:448–454.
  2. Lalla RV, Saunders DP, Peterson DE. Chemotherapy or radiation-induced oral mucositis. Dent Clin North Am. 2014;58:341–349.
  3. I T, Sumita Y, Minamizato T, Umebayashi M, Liu Y, Tran SD, Asahina I. Bone marrow-derived cell therapy for oral mucosal repair after irradiation. J Dent Res. 2014;93:813–820.
  4. Epstein JB, Elad S, Eliav E, Jurevic R, Benoliel R. Orofacial pain in cancer: Part II – Clinical perspectives and management. J Dent Res. 2007;86:506–518.
  5. Viet CT, Corby PM, Akinwande A, Schmidt BL. Review of preclinical studies on treatment of mucositis and associated pain. J Dent Res. 2014;93:868–875.
  6. Chen SC, Lai YH, Huang BS, Lin CY, Fan KH, Chang JT. Changes and predictors of radiation-induced oral mucositis in patients with oral cavity cancer during active treatment. Eur J Oncol Nurs. 2015;19:214–219.
  7. Epstein JB, Schubert MM. Managing pain in mucositis. Semin Oncol Nurs. 2004;20:30–37.
  8. Sonis ST, Elting LS, Keefe D, et al. Mucositis Study Section of the Multinational Association for Supportive Care in Cancer and the International Society for Oral Oncology: Perspectives on cancer therapy-induced mucosal injury: Pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 2004;100(Suppl 9):1995–2025.
  9. Lalla RV, Bowen J, Barasch A, et al. Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO): MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2014;120:1453–1461.
  10. Sonis ST. Oral mucositis in head and neck cancer: Risk, biology, and management. Am Soc Clin Oncol Educ Book. 2013:e236–e240. doi: 10.1200/EdBook_AM.2013.33.e236
  11. Anirudhan D, Bakhshi S, Xess I, Broor S, Arya LS. Etiology and outcome of oral mucosal lesions in children on chemotherapy for acute lymphoblastic leukemia. Indian Pediatr. 2008;45:47–51.
  12. Rajtar B, Polz-Dacewicz M, Filiks-Litwin B, Ziaja-Sołtys M, Stec A, Kowalczyk JR. The prevalence of HCV in youth with onco-hematological diseases. Pol J Environ Stud. 2006;15:329–332.
  13. Winkler O, Hadnagy W, Idel H. Cytokines detectable in saliva of children as appropriate markers of local immunity of the oral cavity: An approach for the use in air pollution studies. Int J Hyg Environ Health. 2001;204:181–184.
  14. Patil CS, Kirkwood KL. p38 MAPK signaling in oral-related diseases. J Dent Res. 2007;86:812–825.
  15. Stokman MA, Spijkervet FK, Boezen HM, Schouten JP, Roodenburg JL, de Vries EG. Preventive intervention possibilities in radiotherapy- and chemotherapy-induced oral mucositis: Results of meta-analyses. J Dent Res. 2006;85:690–700.
  16. Zimmermann C, Meurer MI, Grando LJ, Gonzaga Del Moral JÂ, da Silva Rath IB, Schaefer Tavares S. Dental treatment in patients with leukemia. J Oncol. 2015;2015:571739. doi: 10.1155/2015/571739.
  17. Kung AY, Zhang S, Zheng LW, Wong GH, Chu CH. Oral health status of Chinese paediatric and adolescent oncology patients with chemotherapy in Hong Kong: A pilot study. Open Dent J. 2015;30:21–30.
  18. Karolewska E, Konopka T, Pupek M, Chybicka A, Mendak M. Antibacterial potential of saliva in children with leukemia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008;105:739–744.
  19. Thomaz EB, Mouchrek JC Jr, Silva AQ, et al. Longitudinal assessment of immunological and oral clinical conditions in patients undergoing anticancer treatment for leukemia. Int J Pediatr Otorhinolaryngol. 2013;77:1088–1093.
  20. Månsson-Rahemtulla B, Techanitiswad T, Rahemtulla F, McMillan TO, Bradley EL, Wahlin YB. Analyses of salivary components in leukemia patients receiving chemotherapy. Oral Surg Oral Med Oral Pathol. 1992;73:35–46.
  21. Pajari U, Poikonen K, Larmas M, Lanning M. Salivary immunoglobulins, lysozyme, pH, and microbial counts in children receiving anti-neoplastic therapy. Scand J Dent Res. 1989;97:171–177.
  22. Martín Ibáñez I, Arce Casas A, Cruz Martínez O, Estella Aguado J, Martín Mateos MA. Humoral immunity in pediatric patients with acute lymphoblastic leukemia. Allergol Immunopathol (Madr). 2003;31:303–310.
  23. Potapnev MP, Belevtsev MV, Bortkevich LG, et al. Significance of serum immunoglobulin G for leukocytosis and prognosis in childhood B-lineage acute lymphoblastic leukemia. Pediatr Blood Cancer. 2004;42:421–426.
  24. Pietras W, Chaber R, Pela H, Trybucka K, Chybicka A. The recovery of immune system parameters in children following lymphoblastic leukemia therapy: Preliminary report. Adv Clin Exp Med. 2014;23:97–102.
  25. Pels E. Evaluation of gingival conditions and saliva TNF-α concentration in children with acute lymphoblastic leukemia. Pol J Public Health. 2014;124:81–85.
  26. Pels E. Comparison of saliva interleukin-2 concentration to the condition of gums in children with acute lymphoblastic leukaemia during anti-tumour treatment. Cancer Chemother Pharmacol. 2015;76:205–210.
  27. Gouvêa de Lima A, Villar RC, de Castro G Jr, et al. Oral mucositis prevention by low-level laser therapy in head-and-neck cancer patients undergoing concurrent chemoradiotherapy: A phase III randomized study. Int J Radiat Oncol Biol Phys. 2012;82:270–275.
  28. Pereira Pinto L, de Souza LB, Gordón-Núñez MA, et al. Prevention of oral lesions in children with acute lymphoblastic leukemia. Int J Pediatr Otorhinolaryngol. 2006;70:1847–1851.
  29. de Oliveira Lula EC, de Oliveira Lula CE, Alves CM, Lopes FF, Pereira AL. Chemotherapy-induced oral complications in leukemic patients. Int J Pediatr Otorhinolaryngol. 2007;71:1681–1685.
  30. de Brito Costa EMM, Fernandes MZ, Quinderé LB, de Souza LB, Pinto LP. Evaluation of an oral preventive protocol in children with acute lymphoblastic leukemia. Pesqui Odontol Bras. 2003;17:147–150.
  31. Cheng KK, Chang AM, Yuen MP. Prevention of oral mucositis in paediatric patients treated with chemotherapy: A randomised crossover trial comparing two protocols of oral care. Eur J Cancer. 2004;40:1208–1216.
  32. de Koning BA, Philipsen-Geerling B, Hoijer M, Hählen K, Büller HA, Pieters R. Protection against chemotherapy induced mucositis by TGF-beta(2) in childhood cancer patients: Results from a randomized cross-over study. Pediatr Blood Cancer. 2007;48:532–539.
  33. Fall-Dickson JM, Ramsay ES, Castro K, Woltz P, Sportés C. Oral mucositis-related oropharyngeal pain and correlative tumor necrosis factor-alpha expression in adult oncology patients undergoing hematopoietic stem cell transplantation. Clin Ther. 2007;29(Suppl):2547–2561.
  34. Harris DJ, Eilers J, Harriman A, Cashavelly BJ, Maxwell C. Putting evidence into practice: Evidence-based interventions for the management of oral mucositis. Clin J Oncol Nurs. 2008;12:141–152.
  35. Keefe DM, Schubert MM, Elting LS, et al. Mucositis Study Section of the Multinational Association of Supportive Care in Cancer and the International Society for Oral Oncology: Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer. 2007;109:820–831.
  36. Papas AS, Clark RE, Martuscelli G, O’Loughlin KT, Johansen E, Miller KB. A prospective, randomized trial for the prevention of mucositis in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. 2003;31:705–712.
  37. Li E, Trovato JA. New developments in management of oral mucositis in patients with head and neck cancer or receiving targeted anticancer therapies. Am J Health Syst Pharm. 2012;69:1031–1037.
  38. Scully C, Sonis S, Diz PD. Oral mucositis. Oral Dis 2006;12:229–241.
  39. Treister N, Sonis S. Mucositis: Biology and management. Curr Opin Otolaryngol Head Neck Surg. 2007;15:123–129.
  40. Rhodus NL, Ho V, Miller CS, Myers S, Ondrey MF. NF-κB dependent cytokine levels in saliva of patients with oral preneoplastic lesions and oral squamous cell carcinoma. Cancer Detect Prev. 2005;29:42–45.
© Wroclaw Medical University